Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methyldopate hydrochloride
Drug ID BADD_D01426
Description Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent.[A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals.[A1499] Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form.[A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].[L32619] Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis.[L32624]
Indications and Usage For use in the treatment of hypertension.
Marketing Status Prescription; Discontinued
ATC Code C02AB01
DrugBank ID DB00968
KEGG ID D08205
MeSH ID D008750
PubChem ID 17276
TTD Drug ID D0BA6T
NDC Product Code 52423-0100; 16729-031; 42185-7001; 15894-0038; 16729-030; 67628-3001
Synonyms Methyldopa | alpha-Methyldopa | alpha Methyldopa | alpha-Methyl-L-Dopa | alpha Methyl L Dopa | Alphamethyldopa | Meldopa | Methyldopate | Dopegyt | Dopergit | Dopegit | Sembrina | Apo-Methyldopa | Apo Methyldopa | Dopamet | Aldomet | Hydopa | Nu-Medopa | Nu Medopa
Chemical Information
Molecular Formula C12H18ClNO4
CAS Registry Number 2508-79-4
SMILES CCOC(=O)C(C)(CC1=CC(=C(C=C1)O)O)N.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Libido decreased21.03.02.005; 19.08.03.001--
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
Myalgia15.05.02.001--
Myocarditis02.04.03.001--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nightmare19.02.03.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Orthostatic hypotension17.05.01.020; 24.06.03.004--Not Available
Pancreatitis07.18.01.001--
Paradoxical pressor response24.08.02.003--Not Available
Paraesthesia17.02.06.005--
Parkinsonism17.01.05.003--Not Available
Pericarditis02.06.02.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rheumatoid factor13.06.01.005--Not Available
Sedation17.02.04.005--Not Available
Sialoadenitis07.06.04.002; 11.01.04.002--
Thrombocytopenia01.08.01.002--Not Available
Tongue discolouration07.14.02.006--Not Available
Toxic epidermal necrolysis12.03.01.015; 11.07.01.006; 10.01.01.006; 23.03.01.008--
Vasculitis24.05.02.001; 10.02.02.006--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Carotid sinus syndrome24.03.04.002; 17.04.06.001--Not Available
Lupus-like syndrome10.04.03.003; 23.03.02.004; 15.06.02.004--Not Available
Cerebrovascular insufficiency24.04.06.004; 17.08.02.003--Not Available
Antinuclear antibody positive13.06.01.003--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages